Logo image
Metabolic syndrome and anticonvulsants: A comparative study of valproic acid and carbamazepine
Journal article   Peer reviewed

Metabolic syndrome and anticonvulsants: A comparative study of valproic acid and carbamazepine

A. Rakitin, S. Kõks and S. Haldre
Seizure, Vol.38, pp.11-16
2016
url
Link to Published Version *Subscription may be requiredView

Abstract

Purpose The aim of this study was to compare the risk of metabolic syndrome (MS) and evaluate related factors for MS among people with epilepsy treated with valproate (VPA) or carbamazepine (CBZ). Methods A total of 213 adult patients with epilepsy treated with VPA (n = 118) or CBZ (n = 95) monotherapy were included in the study. Participants were evaluated for the presence of MS, diagnosed according to the National Cholesterol Education Program Adult Treatment Panel III criteria. Results In the multiple logistic regression analysis, the risk of MS in CBZ- and VPA-treated patients was similar (odds ratio [OR] = 0.99; 95% confidence interval [CI], 0.43–2.26; P = 0.979). A lower proportion of CBZ-treated patients had abnormally low levels of high-density lipoprotein cholesterol (OR = 0.10; 95% CI, 0.02–0.42; P = 0.002), whereas a lower proportion of VPA-treated patients had abnormally high concentrations of fasting blood glucose (OR = 0.30; 95% CI, 0.13–0.69; P = 0.004). Females treated with VPA tended to have a higher risk of MS (OR = 1.48; 95% CI, 0.50–4.41; P = 0.485) compared to males (OR = 0.74; 95% CI, 0.28–1.96; P = 0.551), although this difference was not statistically significant. Conclusion Although the overall risk of MS was similar in patients with epilepsy who were treated with VPA or CBZ, the distribution of MS components differed between treatment groups. Patients treated with CBZ or VPA less frequently had decreased high-density lipoprotein cholesterol levels or increased blood glucose concentrations, respectively. Females on VPA treatment could be at higher risk of MS than males.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Citation topics
1 Clinical & Life Sciences
1.222 Epilepsy & Seizures
1.222.143 Epilepsy Treatment
Web Of Science research areas
Clinical Neurology
Neurosciences
ESI research areas
Neuroscience & Behavior
Logo image